J Gynecol Oncol | Volume 3, Issue 1 | Research Article | Open Access

The Prognostic Values and Clinical Implications of m6A Methylation Regulators in Epithelial Ovarian Cancer

Tiefeng C1, Jinhui L1, Xiaoli S2 and Huimin S1*

1Department of Gynecology and Obstetrics, First Affiliated Hospital of Sun Yat-Sen University, China
2Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, USA

*Correspondance to: Huimin Shen 

Fulltext PDF


N6-methyladenosine (m6A) exists in both DNA and RNA modification. RNA m6A modification drives tumor initiation and metastasis through regulating cancer stem cells. However, the detailed mechanisms and the distinct m6A regulatory gene type underlying ovarian cancer mRNA modification remain unclear. Here, we analyzed Copy Number Variation (CNVs) and mRNA expression of ovarian cancer cases in TCGA dataset to determine the copy number variation patterns of m6A regulatory genes, and the associations between m6A dysregulation or certain regulatory gene and overall survival. We showed the KIAA1429, as the writer gene, had highest amplification percentage and were associated with overall survival, or disease-free survival, whereas the associations with prognostic survival were independent of other prognostic factors including stage, grade, and debulking status of the tumour. Besides, METTL14 and YTHDC2, one as the writer gene and the other as reader gene, was also related with clinical outcome. Furthermore, subgroups analysis addressed that m6A upregulation especially writer gain contributed to prognosis in epithelial ovarian cancer. Collectively, our data addressed that m6A upregulation are likely to be critical to the clinical outcome, and KIAA1429 showed the highest correlation with clinical outcome in ovarian cancer among m6A regulatory genes.


RNA modification; Methyltransferase; Demethylases; Epigenetics; Prognostic signature


Tiefeng C, Jinhui L, Xiaoli S, Huimin S. The Prognostic Values and Clinical Implications of m6A Methylation Regulators in Epithelial Ovarian Cancer. J Gynecol Oncol. 2020; 3(1): 1025.

Subscribe to Our Newsletter